𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antibody-based cancer therapies: back to “polyclonals”?

✍ Scribed by Giovanni Paganelli; Rita De Santis

Publisher
Springer
Year
2004
Tongue
English
Weight
133 KB
Volume
31
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant polyclonal antibodies for ca
Recombinant polyclonal antibodies for cancer therapy
✍ Jacqueline Sharon; Meredith A. Liebman; Brent R. Williams 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

## Abstract Although monoclonal antibodies are increasingly used for cancer therapy, remissions are only temporary due to emergence of tumor cell escape variants that are no longer affected by the antibody. The emergence of escape variants could be minimized by multi‐targeting of tumor cells with p

Introduction to the supplement, “Cancer
Introduction to the supplement, “Cancer Therapy with Antibodies and Immunoconjugates”
✍ David M. Goldenberg 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract This supplement includes 16 representative articles presented at the 12^th^ Conference on Cancer Therapy With Antibodies and Immunconjugates, Parsippany, New Jersey, October 16‐18, 2008, encompassing cancer treatment with unconjugated and isotope‐conjugated antibodies targeting selectiv

The differentiation antigen NY-BR-1 is a
The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer
✍ Inka Seil; Claudia Frei; Holger Sültmann; Shirley K. Knauer; Knut Engels; Elke J 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 976 KB

## Abstract Antibody‐based cancer immunotherapy relies on the identification and characterization of target antigens and the development of potent antibodies recognizing the target. Here we report the expression analysis and molecular characterization of the differentiation antigen NY‐BR‐1, which w